Daily Stock List
Stellar Biotechnologies, Inc. (SBOTF)
SeriousTraders, FeedBlitz, and Streetwise Reports reported earlier on Stellar Biotechnologies, Inc. (SBOTF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Based in Port Hueneme, California, Stellar Biotechnologies, Inc. is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This protein has a highly complex structure that makes it ideal for use in human and animal vaccines as well as diagnostic products. The founding of Stellar Biotechnologies was to address the growing demand for renewable, commercial-scale supplies of high quality, GMP-grade KLH. The Company has developed leading practices, facilities and proprietary capabilities to address this need.
Stellar serves the rapidly growing demand for the essential molecule (KLH) in pharmaceutical and diagnostic markets. They ensure supply of the highest quality, GMP-grade KLH protein. They are developing a collection of novel KLH assays and products for immunological use. KLH is an important immunostimulating protein derived only from a limited natural source. Stellar manufactures Stellar KLH™, known for its high purity and immunogenicity.
The Company has generated important intellectual property (IP). This IP relates to aquaculture technologies, spawning, selection and maintenance of the limited natural source of this pharmaceutical material (Megathura crenulata), as well as processing, purification and engineering of specific stabilized formulations of this protein. KLH is a potent immune-stimulating protein used in a new class of drugs known as conjugate vaccines.
KLH is used as an essential carrier protein in vaccines undergoing development for use in oncology, cardiology, rheumatology, neurology, and other important clinical indications. KLH is also extensively used as a standard antigen in diagnostic applications including immunotoxicology and assessment of immune status.
At the end of April, Stellar Biotechnologies announced publication of a peer-review article on Clostridium difficile (C. difficile) in the current issue of Expert Review of Vaccines (April 2013, Vol. 12, No.4.). The paper, titled "Carbohydrate-based Clostridium difficile Vaccines", was co-authored by scientists from Stellar Biotechnologies, the University of Arizona, and the University of Guelph (Ontario, Canada). In 2012, Stellar entered into an agreement with the University of Guelph for the exclusive option to license technology for the development of a vaccine candidate against C. difficile. Currently, Stellar is evaluating KLH-conjugate vaccine candidates in preclinical studies.
Last week, Stellar Biotechnologies, announced the presentation of a poster at the Annual 2013 National Science Foundation (NSF) Conference in Baltimore, Maryland, highlighting their achievements in developing methods related to the sustainable cultivation of the ocean mollusk - the sole source for Keyhole Limpet Hemocyanin (KLH). KLH protein is only derived from the Giant Keyhole Limpet (Megathura crenulata). This is a scarce sea mollusk native to the Pacific Coast waters off California.
Stellar Biotechnologies, Inc. (SBOTF), closed Friday's trading session at $0.7993, up 14.19%, on 729,681 volume with 230 trades. The average volume for the last 60 days is 64,346 and the stock's 52-week low/high is $0.191/$0.7808.
Texas Rare Earth Resources Corp. (TRER)
Pro-Edge reported yesterday on Texas Rare Earth Resources Corp. (TRER), Alliance Advisors did last week, Wall Street Resources and Streetwise Reports did previously, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Based in Sierra Blanca, Texas, Texas Rare Earth Resources Corp. is a mining company engaging in the business of the acquisition, exploration and development of mineral properties. Listed on the OTCQX U.S., they currently hold a lease to explore and develop a rare earth minerals project (Round Top) located in Hudspeth County, Texas, and prospecting permits covering an adjacent 9,345 acres. In addition, Texas Rare Earth Resources holds prospecting permits on certain other mineral properties located in New Mexico.
The Company's flagship Round Top project is approximately 85 miles southeast of El Paso. Texas Rare Earth holds 19-year renewable leases from the State of Texas on 950 acres encompassing Round Top and additional prospecting permits on adjacent areas covering the aforementioned additional 9,345 acres. The Company is presently focusing on the exploration and development of rare earth elements at Round Top.
Texas Rare Earth Resources also has their Silver Project in the Macho District, in Sierra County, New Mexico. The Macho property consists of 12 unpatented mining claims covering a set of northeast trending silver-lead veins.
Recently, the Company announced third party confirmation by ALS Ltd. of Canada of in-house research, which indicates the possibility of heap leaching Round Top rock. The Company indicates that coarse ore leaching at room temperature has been shown to recover 85 percent Yttrium and 81 percent Dysprosium in an independent study. The Company also indicates that a breakthrough discovery of Beryllium and Lithium recovery from Round Top rhyolite holds additional potential revenue opportunity. The Study paves the way for potential major capital cost savings.
This week, Texas Rare Earth Resources announced the appointment of Mr. Anthony Marchese as Non-Executive Chairman of the Board. Mr. Marchese served as a Director of the Company and Chairman of the Audit Committee since December of 2009. The Company also appointed Ms. Laura Lynch to the Board of Directors. Ms. Lynch is currently a Partner at the CL Ranch, a ranching/farming/mining operation in Hudspeth County. CL ranch is active in the mining and distribution of gypsum.
Texas Rare Earth Resources Corp. (TRER), closed Friday's trading session at $0.30, up 3.45%, on 243,981 volume with 37 trades. The average volume for the last 60 days is 81,835 and the stock's 52-week low/high is $0.14/$0.80.
BioNitrogen Corp. (BION)
Stock Analyzer, Wall Street Stallions, FeedBlitz, SmallCapVoice, and Top Secret IPO reported previously on BioNitrogen Corp. (BION), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Doral, Florida, BioNitrogen Corp. is a cleantech company whose shares trade on the OTC Pink Current Information. The Company utilizes proprietary technology to build environmentally friendly plants that convert biomass into Urea fertilizer. Urea is a white, crystalline solid containing 46 percent Nitrogen. Its main use is in the agricultural industry as a crop fertilizer. BioNitrogen's corporate mission is to provide safe, cost effective, green solutions, which are economically beneficial in locations where biomass is produced and urea is consumed.
The Company's unique, patent-pending technologies will transform residual agricultural waste and other biomass materials into high-quality bulk urea. This is for sale to agricultural wholesalers as well as retailers. Their facilities will be able to manufacture 15 tons of urea fertilizer per hour for total annual production of approximately 124,200 tons per plant. BioNitrogen's facilities are modular in design and significantly smaller than traditional urea production plants.
BioNitrogen will produce urea in three principal product formats. These are Granular Urea – 46 percent Nitrogen content; Prilled Urea – 46 percent Nitrogen content, and Urea Ammonium Nitrate (UAN) – 32 percent Nitrogen content.
The BioNitrogen concept is to gasify biomass feedstock and convert the resulting gas into urea. The biomass will be dried, cleaned and ground to a consistent size and gasified. The resultant raw synthetic natural gas (syngas) will subsequently pass through a series of cleaning steps to remove any elements that could be detrimental to the downstream processing.
The clean syngas will then pass through a series of catalytic reaction stages for transformation into the desired product; specific chemicals will be separated out and recycled to the suitable points in the process. Because of the recycling, there will be no requirement for byproduct vent streams. Consequently, up to 100 percent of the feed carbon content can undergo conversion to syngas and/or the final product, urea.
In April, BioNitrogen announced that they started collection of woody biomass from phosphate mining and non-mining lands to use for urea fertilizer production. The collected biomass will supply the Company's first plant in Hardee County, Florida. In the interim pre-construction period, the excess biomass may also be processed and sold as wood chips to the global marketplace to generate revenues. This year, the Company expects to receive a minimum of 30,000 tons of biomass from mining and other sources every two months at the Hardee County plant site.
BioNitrogen Corp. (BION), closed Friday's trading session at $0.075, even for the day, on 1,127,892 volume with 47 trades. The average volume for the last 60 days is 295,034 and the stock's 52-week low/high is $0.02/$0.44.
Rand Worldwide, Inc. (RWWI)
FeedBlitz reported recently on Rand Worldwide, Inc. (RWWI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Market's OTCQB, Rand Worldwide, Inc. is a leading provider of technology solutions and professional services to the engineering community. Rand Worldwide is not affiliated with RAND Corporation. Rand Worldwide targets organizations in the building, infrastructure and manufacturing industries. The Company has their corporate headquarters in Framingham, Massachusetts.
The Company provides wide-ranging solutions that enable companies to better leverage technology, improve workflow processes, and enhance the skills of their people. Rand Worldwide Divisions include ASCENT- Center for Technical Knowledge; IMAGINiT Technologies; Rand 3D; Rand Facilities Management, and Rand Secure Archive.
Recently, Rand Worldwide announced that their IMAGINiT Technologies division released the 2014 versions of IMAGINiT Clarity, IMAGINiT Clarity LT and IMAGINiT Clarity Workshare. These three web-based collaboration tools additionally include new and improved features. Each of these web-based collaboration tools provides task automation, project reporting, and system monitoring and project level security. These are to provide easy sharing of BIM data inside organizations and among external partners.
The IMAGINiT Technologies division of Rand Worldwide advances the way architects and engineers design, develop, and manage projects. IMAGINiT Technologies' customers include organizations in the building, infrastructure, manufacturing and facilities management industries. This division's team is one of the world's largest integrators of Autodesk 3D design and engineering software.
Additionally, Rand Worldwide recently announced their financial results for the three and nine months ended March 31, 2013. For the three months ended March 31, 2013, they reported total revenues of $26.1 million, in comparison to $22.4 million in the same quarter for the prior fiscal year. Their overall gross margin percentage for the current quarter was 52.1 percent. This represents an increase over the 50.6 percent that they reported for the quarter ended March 31, 2012. The Company reported net income of $1,775,000, or $0.03 per fully diluted share, compared with net income of $1,639,000, or $0.03 per share, for the same period a year ago.
For the nine months ended March 31, 2013, Rand Worldwide reported total revenues of $69.3 million versus $66.8 million in the prior year. Year to date net income was $2,847,000, or $0.05 per fully diluted share. This is in comparison to net income of $3,080,000, or $0.05 per share, reported for the same period in the prior year.
Rand Worldwide, Inc. (RWWI), closed Friday's trading session at $0.875, down 1.69%, on 3,000 volume with 3 trades. The average volume for the last 60 days is 31,301 and the stock's 52-week low/high is $0.66/$0.94.
Monitise plc (MONIF)
Today we are highlighting Monitise plc (MONIF), here at the QualityStocks Daily Newsletter.
Monitise plc is the largest Mobile Money (banking, paying and buying with a mobile device) specialist in the world. The Company works with more than 300 of the world's foremost businesses and financial institutions across global territories. Monitise provides mobile banking, payments, and commerce solutions. Their solutions enable financial institutions and other service providers to offer diverse services to their clientele. Founded in 2003, the Company lists on the OTC Pink Current Information. Monitise has their headquarters in London, the United Kingdom (UK).
More than 20 million consumers benefit from the Company's patented technology to 'bank anywhere', 'pay anyone' and 'buy anything'. This accounts for more than $30 billion of payments, purchases and transfers each year. Monitise maintains strategic partnerships with leading companies including Visa, Inc., Visa Europe, RBS Group and FIS to develop and implement Mobile Money services. Monitise powers bank-grade solutions that undergo delivery on-premise or by way of cloud services.
The Monitise Enterprise Platform is an evolving hardware and software technology resource. It delivers unique mass-market mobile banking, payment and commerce solutions for financial institutions and their clients. The Monitise Enterprise Platform's bank grade security ensures that financial institutions' mobile services undergo delivery with complete confidence to any device, from a basic phone to the latest smartphone, tablet and more.
This week, Blackhawk Network, Inc. (HAWK) and Monitise announced an agreement to make mobile gift card purchasing available to consumers via certain banks and financial institutions in the U.S. Moreover, the companies' intention is to expand their relationship into additional markets. Blackhawk Network is a leading prepaid payment network. They use proprietary technology to offer a wide array of gift cards, other prepaid products and payment services in the U.S as well as 18 other countries.
Prepaid gift cards from Blackhawk Network's GiftCardMall™ will be available to consumers for purchase from participating banks and payment companies' mobile wallets, powered by Monitise. Blackhawk Network's wide-ranging network will integrate into Monitise's mobile banking ecosystem. This will make it easier for consumers to buy Blackhawk gift cards from popular retail brands through mobile.
Monitise plc (MONIF), closed Friday's trading session at $0.635, up 0.83%, on 1,126,047 volume with 203 trades. The average volume for the last 60 days is 659,736 and the stock's 52-week low/high is $0.37/$0.69.
Pacific Iron Ore Corp. (POC.V)
Today we are highlighting Pacific Iron Ore Corp. (POC.V), here at the QualityStocks Daily Newsletter.
Pacific Iron Ore Corp. engages in the exploration and development of mineral properties in Canada. The Company explores for gold, silver, copper, and iron ore. Pacific Iron Ore formed on July 3, 2008 by way of an amalgamation agreement to combine privately held Emerald Fields Resource Corp. and publicly traded Klondike Capital Corp. Pacific Iron Ore lists on the TSX Venture Exchange. The Company is based in Calgary, Alberta.
Pacific Iron Ore's portfolio includes eight mineral properties in Canada. These are situated on the southwestern edge of Vancouver Island and in northwestern Ontario. As of March 31, 2011, their Vancouver Island holdings totaled 170,648 hectares at 100 percent working interest. The focus of the Company's exploration program, the Pearson Project on Vancouver Island, has the potential for major high-grade deposits of iron ore and other metals.
As of March 31, 2011, Pacific Iron Ore additionally holds several mining properties in Ontario totaling 15,472 hectares (110 mining claims and 15 leases). The Company's Ontario properties are in a region with proven potential for a number of metals and commodities.
However, last week, Pacific Iron Ore announced that they entered into an agreement with a private, arm's length British Columbia Corporation. Pacific Iron Ore agreed to sell all of their interests in the Pearson Project mineral claims prospective for iron ore for $5.6 million. The Company's intention, upon completion of the transaction, is to focus their exploration on their 100 percent owned St. Anthony's gold project located in the Kenora Patricia mining district of the Province of Ontario.
In addition, last week, Pacific Iron Ore announced that they filed their Financial Statements and Management Discussion and Analysis for the three months ended March 31, 2013. During the first three months of 2013, they incurred a net loss of $74,149 or $0.00 per common share. This is in comparison to a net loss of $151,692 or ($0.00) per common share in the first three months of 2012. Net financial expenses (income) during the period were $11,907 versus ($157) income in the prior period. Financial income consists of interest earned on invested cash deposits and unrealized gains or losses on marketable securities.
Pacific Iron Ore Corp. (POC.V), closed Friday's trading session at $0.035, up 16.67%, on 20,000 volume. The stock's 52-week low/high is $0.03/$0.08.
Lignol Energy Corp. (LEC.V)
Today we are reporting on Lignol Energy Corp. (LEC.V), here at the QualityStocks Daily Newsletter.
Listed on the TSX Venture Exchange, Lignol Energy Corp. (LEC) is a leading technology company in the advanced biofuels and renewable chemicals sectors. In addition, LEC's intention is to invest in, or otherwise obtain, equity interests in energy related projects that have synergies with the Company and have the potential to generate near term cash flow. The Company (LEC) owns 100 percent of the issued and voting shares of Lignol Innovations Ltd. (LIL). LEC is the majority shareholder of TBF. Additionally, LEC owns 21.4 percent of the largest producer of biodiesel in Australia, Australian Renewable Fuels Ltd. (ARW.AX) (ARW).
Lignol Innovations (LIL) engages in the development of biorefining technologies for the production of advanced biofuels. These include fuel-grade ethanol, and other renewable chemicals from non-food cellulosic biomass feedstocks. LIL is working on their development plan, by way of strategic partnerships, to further develop and integrate their core technologies on a commercial scale.
Their modified solvent-based pre-treatment technology facilitates the fast, high-yield conversion of cellulose to ethanol and the production of value-added biochemical co-products, including high purity HP-LTM lignin. HP-LTM lignin represents a new class of high purity lignin extractives (and their subsequent derivatives). These can undergo engineering to meet the chemical properties and functional requirements of a spectrum of industrial applications that until now has not been possible with traditional lignin by-products generated from other processes.
Last week, LEC announced that they agreed to acquire an additional 2.67 million shares of Territory Biofuels Ltd. (TBF) for A$1 million under a TBF private placement offering transaction that also provides for the further issuance of approximately 0.25 million shares of TBF to other shareholders of TBF. LEC, upon completion, will become the majority shareholder with approximately 56 percent of the issued shares of TBF and 60 percent on a fully diluted basis. TBF owns a large-scale biorefining facility located in Darwin, Northern Territory, Australia. This facility includes a Lurgi designed biodiesel plant and the only glycerine refinery in Australia.
Mr. Ross MacLachlan, Chief Executive Officer and Chairman of LEC, said, "We are excited to be working with the TBF team and adding our support as the majority shareholder in planning the re-start of the Darwin refinery. Our goal is to have the refinery come back on line in Q4 2013, and incorporate upgrades to process lower cost feedstocks that will enhance profitability in 2014. This is an important milestone for our company and represents the potential for us to accelerate our transition to commercial operations with a majority equity stake in a world scale biofuels project."
Lignol Energy Corp. (LEC.V), closed Friday's trading session at $0.08, even for the day. The stock's 52-week low/high is $0.05/$0.18.
RJD Green, Inc. (RJDG)
Penny Stock Newsletter, Market Bulls, Damn Good Penny Picks, The Bull Exchange, and GaintheGreen reported today on RJD Green, Inc. (RJDG), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
RJD Green, Inc. is a development company focusing on green services and products. The Company's recently acquired subsidiary, Silex Holdings, Inc. formed in 2012 to acquire and manage high growth assets and business enterprises. RJD Green acquired 100 percent of the issued and outstanding shares of Silex Holdings and Silex Holdings received approximately 88 percent of the issued and outstanding shares of RJD Green. RJD Green has their corporate headquarters in Mississauga, Ontario. The Company's shares trade on the OTC Markets' OTCQB.
Their subsidiary, Silex Holdings, focuses in three divisions. RJD Green is continuing to grow each division via acquisition of growth capable companies that offer synergistic operations, and internal growth of each enterprise. The three divisions are Energy companies; Green-technology based Environmental companies, and Specialty Niche Building Material Enterprises.
Energy has a current focus in oil production and property development, and oil and gas products and services. Environmental Services has green-technology based environmental services as a principal focus. The Specialty Niche Building Material Enterprise is pursuing opportunities that are synergistic in corporate needs and have harmony of sales and marketing efforts.
In late 2012, RJD Green acquired an operating company in the building materials division with 7 years of operation and $2,400,000 mean revenues YOY (Year-over-Year). Green technologies were acquired in the environmental and energy sectors. The projection is that the twelve month pro forma, post-merger, will be greater than $17,000,000 with current acquisitions being fully launched.
RJD Green's intention is to design and develop an online directory for green building supplies, green builders, appliances, as well as other green technologies for home building.
Concerning the Silex Holdings acquisition, RJD Green Chief Executive Officer, Mr. Rex Washburn, stated that, "both companies are excited about the ability [to] move forward in mutual focus within green products and services and oil and gas enterprise that is expected to bring mutual long-term benefit to both companies and their shareholders."
RJD Green, Inc. (RJDG), closed Friday's trading session at $0.199, up 3.11%, on 2,723,474 volume with 552 trades. The average volume for the last 60 days is 254,481 and the stock's 52-week low/high is $0.05/$0.25.
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.05, up 29.87%, on 3,063,062 volume with 139 trades. The stock’s average daily volume over the past 60 days is 1,984,084, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. announced the submission today of an Application for Orphan Drug Designation with the U.S. FDA Office of Orphan Products Development for ADXS-HPV, the company's leading drug candidate for the treatment of invasive cervical cancer. CSO of ADXS, Dr. Robert Petit, expressed confidence about the request for Orphan Drug Designation citing data from the recent Phase 2 study to indicate the company may have their hands on a real solution for unmet medical need represented by cervical cancer.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer with ADXS-HPV
Advaxis Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time
Advaxis Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.22, up 28.65%, on 55,691 volume with 23 trades. The stock’s average daily volume over the past 60 days is 49,178, and its 52-week low/high is $0.041/$0.98.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals, Inc. Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
Rafarma Pharmaceuticals, Inc. Announces Engagement of QualityStocks Investor Relations Services
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
VentriPoint Diagnostics Ltd. (VPTDF)
The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.0805, up 7.62%, on 60,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 17,487, and its 52-week low/high is $0.073/$0.163.
VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer
VentriPoint Diagnostics Ltd. Company Blog
VentriPoint Diagnostics Ltd. News:
Ventripoint Announces New Vice-President of Sales and Marketing
VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt
VentriPoint Announces Private Placements
Solar Wind Energy Tower, Inc. (SWET)
The QualityStocks Daily Newsletter would like to spotlight Solar Wind Energy Tower, Inc. (SWET). Today, Solar Wind Energy Tower, Inc. closed trading at $0.025, up 4.17%, on 111,045 volume with 14 trades. The stock’s average daily volume over the past 60 days is 772,163, and its 52-week low/high is $0.01/$0.08.
Solar Wind Energy Tower, Inc. (SWET) is focused on commercializing a number of proven, validated technologies and construction systems into a single large Solar Wind Downdraft Tower structure that produces abundant, inexpensive electricity. The company's core objective is to become a leading provider of clean, efficient energy at a reasonable cost, while continuing to generate innovative technological solutions for tomorrow's electrical power needs.
The company's cutting-edge energy solution generates clean energy by harnessing the natural power of a downdraft created within the confines of a Solar Wind Downdraft Tower structure. Using benevolent, non-toxic natural elements, the solar/wind hybrid technology is capable of being operated with virtually no carbon footprint, fuel consumption, or waste production. To view a demonstration of the tower, visit http://dtg.fm/4Gp7.
The business plan employed by Solar Wind Energy includes partnering with various entities, such as utilities, sovereign nations, and independent power sources, to bring this solution to the market as rapidly as possible. The company's role would consist of facilitating the Tower's development with its expertise and intellectual property. Revenue streams include development fees, licensing fees, and royalties on power sales from each project and/or ownership interests.
Solar Wind Energy has assembled a team of experienced business professionals, as well as engineering and scientific consultants, with the proven ability to bring new ideas to market. The company has also filed and been issued patents that protect its revolutionary technology and leading position in the continual global pursuit to meet rising demand for energy. Disclaimer
Solar Wind Energy Tower, Inc. Company Blog
Solar Wind Energy Tower, Inc. News:
Solar Wind Energy Tower, Inc. CEO Featured in Exclusive QualityStocks Interview
Solar Wind Energy Tower, Inc. Receives Notice of Allowance of Patent titled "Atmospheric Energy Extraction Devices and Methods"
Solar Wind Energy Tower, Inc. Partners with Commonwealth Dynamics, Inc.
Advaxis, a clinical-stage biotech company focused on developing the next generation of immunotherapies for cancer and infectious diseases, has submitted an application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) Office for ADXS-HPV, the company’s lead drug candidate for the treatment of invasive cervical cancer.
“We are optimistic about our request for Orphan Drug Designation for ADXS-HPV in the indication of invasive cervical cancer,” Dr. Robert Petit, chief scientific officer of Advaxis stated in the press release.
The company recently presented data from its phase II study of ADXS-HPV at the 2013 ASCO Annual Meeting, demonstrating DXS-HPV as an active treatment for cervical cancer, with the potential to become a non-chemotherapy treatment option capable of improving survival for women with cervical cancer.
“We believe that ADXS-HPV will become an important new treatment for this unmet medical need. Orphan Drug Designation could expedite our ability to help women with cervical cancer worldwide, including the 12,340 U.S. women the American Cancer Society estimates will be newly diagnosed in 2013,” Dr. Petit added.
The FDA grants Orphan Drug Designation to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people. The designation provides the company with several advantages.
“If granted, Orphan Drug Designation for our lead product candidate, ADXS-HPV, for the treatment of human papillomavirus, or HPV, associated cervical cancer, would provide the opportunity to gain several very key incentives for Advaxis, including the potential for seven years of market exclusivity for ADXS-HPV if the product is approved by the FDA, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of certain significant administrative filing fees,” Daniel J. O’Connor, executive vice president of Advaxis stated. “These incentives, if achieved, will increase the potential value of ADXS-HPV.”
For more information visit www.advaxis.com
StreamTrack is a digital media and technology services company providing audio and video streaming and advertising services through its RadioLoyalty™ platform – the company’s target market is Internet and terrestrial radio stations, Internet radio guides, and other broadcast content providers worldwide.
The company is also continuing its development of WatchThis™, a patent-pending technology that will provide Web, mobile and IP television streaming services that are e-commerce enabled within streamed content.
StreamTrack has established a network of partners that includes more than 1,300 Internet and terrestrial radio stations in the United States, the largest IPTV provider in Asia, and one of the leading Internet radio guides in the United States. The company has also formed an alliance with PPTV, China Mobile Entertainment Holdings, LTD and most recently, One World Media Group,to execute its strategy of offering Internet radio on a global scale.
StreamTrack’s mission is to equip broadcasters and publishers with the tools necessary to maximize their revenue and decrease, or eliminate their expenses. To fulfill this goal, the company offers an array of solutions ideal for agencies and advertisers, publishers and broadcasters, mobile providers, and developers and partners: video; display advertising; mobile marketing; and virtual currency, such as redeemable loyalty points.
For more information visit www.streamtrack.com
MMRGlobal subsidiary MyMedicalRecords, Inc., WebMD Health Corp. and WebMD Health Services Group, Inc. (collectively, WebMD) have entered into an agreement to dismiss a patent infringement case filed by MMRF against WebMD in February 2013.
Per the agreement, the case is dismissed without prejudice to re-filing the same case again, which means MMRF retains the right to re-file the litigation at any time. However, the companies will try and resolve the matter without the timing constraints imposed by the lawsuit.
MMRF provides online Personal Health Records (PHRs) and electronic safe deposit box storage solutions for consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The company’s subsidiary, MyMedicalRecords is built on proprietary, patented technologies by company CEO Robert H. Lorsch.
“As a former arbitrator for the American Arbitration Association, I learned from firsthand experience that resolving disputes privately at a table is always my preferred course of action when compared to spending millions of dollars in legal fees over years in a courtroom. As the inventor of MMR’s health IT patent portfolio, I see this announcement as a positive development for the company,” Lorsch stated in the press release. “The purpose in filing our patents has always been to protect MMR’s constitutional right to own property and sell the products and services which include our patented IP. We hope this will be the first of many similar opportunities to build business relationships at the negotiating table with hospitals, providers, vendors and others who may be infringing on the company’s IP.”
The suit against WebMD is one of several ongoing patent infringement cases filed by MMRF, both domestically and abroad. MMRF has filed similar suits against Jardogs LLC, a subsidiary of Allscripts.
“While we continue to pursue additional licensing opportunities, we remain confident in the value of our seven issued U.S. patents and global patents in 12 countries around the world. MMR remains committed to aggressively leveraging our portfolio of health information technology patents in the marketplace to obtain the highest value for our stockholders, employees and vendors,” Lorsch stated.
For more information visit www.mymedicalrecords.com
OTC Markets Group, which has helped to completely overhaul the OTC space with the OTCQX and OTCQB on their SEC-regulated OTC Link® ATS, has hailed the recent SEC decision to update their compliance and disclosure interpretations (May 16, see Question 139.13) with great pride, as the SEC finally starts to treat the “pinksheets” according to the new relevance paradigm created by the real-time technological proficiency of the burgeoning OTC Link.
This is the recognition well-earned for having done over a decade’s worth of technology, transactional efficiency, transparency, and regulatory framework upgrades, implemented through OTC Link, which is now larger than the FINRA-controlled OTCBB. The SEC is basically saying with this move that, because FINRA is a registered SRO and regulates/oversees broker-dealers irrespective of the quotation system, and because OTC Link is now a more prominent and accurate real-time index of the market as a whole (applications go through FINRA and both BB/Link require a valid 15c2-11), the decision makes perfect sense, especially considering how 99% of OTCBB eligible securities are already quoted on OTC Link anyways.
This essentially puts OTCBB in the history books as the torch is passed to a new generation of real-time market transparency and OTCM is already chomping at the bit, eager to spend their clout earned by overhauling the space, with submission of a comment letter to the SEC urging expansion of the relevant Form 13(f) reporting requirements to encompass all equity securities across the entire spectrum of the OTCQX and OTCQB, as well as the OTC Pink marketplace. This move by the SEC is a clear decision to treat these marketplaces as “established public markets” and to take full advantage of their capacity to firmly establish a public market price in equity line financing security registration.
Today’s traders know the score, there is no question which is the truly 21st century inter-dealer quotation/trading system out of the OTCBB and OTC Link. OTCM knows this and is moving to take the wheel, confident in their proven formula for creating intuitive, easy to interact with, and highly transparent markets. Previously, all three tiers of the OTC Link were looked down on as mere “pinksheets” by SEC personnel, but that era is clearly withering on the vine as the SEC sets a new standard, according OTCQX/OTCQB the proper significance.
This is great news for many companies who can now use their OTCQX or OTCQB marketplace designation to execute an equity line financing registration statement and are subsequently able to rely on quotes off the OTC Link ATS when establishing a public market price when as they go to raise capital. While the SEC essentially analyzes private equity line financings as indirect primary offerings, this move is a firm recognition of the prevailing demand for the ‘resale’ form of registration sought in such financings and will allow companies to register the ‘resale’ of the securities prior to exercise of the associated put if the transactions meet certain criteria (again, see Question 139.13), thus aligning the transaction more with the state of a primary offering. Basically, the differentiating factor here was the delayed nature of the puts and a lack of risk resulting from a (procedurally intangible) formula price, but the stated criteria and immediacy of the OTC Link ATS itself offers a powerful framework to justify the SEC modification.
OTC Link gives broker-dealers the power needed to control their trades and counterparties, resulting in highly optimized execution and improved order flow generation, all within a tight FINRA/SEC compliance envelope.
For more info on OTC Markets Group, Inc. visit www.OTCMarkets.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Requests Orphan Drug Designation for Treatment of Cervical Cancer with ADXS-HPV
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
- DoMark International, Inc. (DOMK) Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market
- GNCC Capital, Inc. (GNCP) Nears Completion of the Acquisition of the White Hills Gold Properties
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- International Stem Cell Corp. (ISCO) Initiates IND-Enabling Study in Parkinson's Disease Program
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Announces Engagement of QualityStocks Investor Relations Services
- Rafarma Pharmaceuticals, Inc. (RAFA) Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
- Rainbow Coral Corp. (RBCC) Poised To Gain Share Of $142 Billion Market
- Raptor Resources Holdings Inc. (RRHI) Announces Engagement of QualityStocks Investor Relations Services
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
- The Aristocrat Group Corp. (ASCC) Targets August Sales Debut for RWB Ultra-Premium Gluten-Free Vodka
- The Guitammer Company Inc. (GTMM) Goes Supersonic!
- VentriPoint Diagnostics Ltd. (VPTDF) Announces New Vice-President of Sales and Marketing
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue